Cargando…

TET2, ASXL1, IDH1, and IDH2 Single Nucleotide Polymorphisms in Turkish Patients with Chronic Myeloproliferative Neoplasms

We aimed to determine the genotype distribution, allele frequency, and prognostic impact of IDH1/2, TET2, and ASXL1 single nucleotide polymorphisms (SNPs) in myeloproliferative neoplasms (MPNs). TET2 (rs763480), ASXL1 (rs2208131), and IDH1 (rs11554137) variant homozygous genotype frequencies were fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Soyer, Nur, Tezcanlı Kaymaz, Burçin, Cömert Özkan, Melda, Aktan, Çağdaş, Küçükaslan, Ali Şahin, Şahin, Fahri, Kosova, Buket, Saydam, Güray
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Galenos Publishing 2017
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440870/ https://www.ncbi.nlm.nih.gov/pubmed/28218607 http://dx.doi.org/10.4274/tjh.2016.0401

Ejemplares similares

Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms
por: Soyer, Nur, et al.
Publicado: (2017)

Quality of Life and Supportive Care in Multiple Myeloma
por: Cömert, Melda, et al.
Publicado: (2013)

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
por: Tefferi, A
Publicado: (2010)

Molecular Evaluation of t(14;18)(bcl-2/IgH) Translocation in Follicular Lymphoma at Diagnosis Using Paraffin-Embedded Tissue Sections
por: Selvi, Nur, et al.
Publicado: (2012)

Extramedullary Relapse in a CML Patient after Allogeneic Stem Cell Transplantation
por: Yilmaz, Asu Fergun, et al.
Publicado: (2017)

Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms
por: Lasho, Terra L., et al.
Publicado: (2018)

Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias
por: Rocquain, Julien, et al.
Publicado: (2010)

High Frequency of ASXL1 and IDH Mutations in Young Acute Myeloid Leukemia Egyptian Patients
por: El Nahass, Yasser H, et al.
Publicado: (2022)

PB2652: EVALUATION OF 6 CASES WITH FXIII DEFICIENCY: SINGLE CENTRE EXPERIENCE
por: Sahin, Fahri, et al.
Publicado: (2023)

PB2645: HEMATURIA IN ADULT HAEMOPHILIC INDIVIDUALS: IS THE HEMAOPHILIA THE ONLY CAUSE OF HEMATURIA? A SINGLE CENTRE EXPERIENCE FOR A DECADE
por: Tüzün, Betül Kübra, et al.
Publicado: (2023)

JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition
por: McKenney, Anna Sophia, et al.
Publicado: (2018)

IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
por: Cerchione, Claudio, et al.
Publicado: (2021)

Adherence to hemophilia patients with prophylaxis: Veritas-Pro and psychometric properties adapted to Turkish
por: Mehrekula Demirci, Zuhal, et al.
Publicado: (2023)

Disruption of asxl1 results in myeloproliferative neoplasms in zebrafish
por: Gjini, Evisa, et al.
Publicado: (2019)

Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2
por: Guilhamon, Paul, et al.
Publicado: (2013)

Exome sequencing identifies frequent genomic loss of TET1 in IDH-wild-type glioblastoma()()
por: Stasik, Sebastian, et al.
Publicado: (2020)

Distinct and opposite effects of leukemogenic Idh and Tet2 mutations in hematopoietic stem and progenitor cells
por: Fortin, Jerome, et al.
Publicado: (2023)

Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH Mutations in Glioblastoma
por: Krell, Daniel, et al.
Publicado: (2011)

Sleeve Gastrectomy in a Severe Hemophilia A Patient: One of the Very Rare Cases
por: Davulcu, Eren Arslan, et al.
Publicado: (2020)

Estimation of the occurrence rates of IDH1 and IDH2 mutations in gliomas and the reconsideration of IDH-wildtype anaplastic astrocytomas: an institutional experience
por: Cho, Uiju, et al.
Publicado: (2021)

Mutant IDH1 is required for IDH1 mutated tumor cell growth
por: Jin, Genglin, et al.
Publicado: (2012)

IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression
por: DiNardo, Courtney D, et al.
Publicado: (2015)

IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives
por: Mondesir, Johanna, et al.
Publicado: (2016)

IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution
por: Rodriguez, Erika F., et al.
Publicado: (2020)

Deep Learning Can Differentiate IDH-Mutant from IDH-Wild GBM
por: Pasquini, Luca, et al.
Publicado: (2021)

Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL
por: Simonin, Mathieu, et al.
Publicado: (2021)

Concurrent IDH1 and IDH2 mutations in glioblastoma: A case report
por: Haider, Ali S., et al.
Publicado: (2023)

PB1937: A RARE, DIFFICULT- TO- DIAGNOSE DISEASE; LANGERHANS CELL HISTIOCYTOSIS – A SINGLE CENTRE EXPERIENCE
por: Tüzün, Betül Kübra, et al.
Publicado: (2023)

Adult Onset Langerhans Cell Histiocytosis: Clinical Characteristics and Treatment Outcomes
por: Arslan Davulcu, Eren, et al.
Publicado: (2023)

The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas
por: Wang, Hao-Yuan, et al.
Publicado: (2016)

DDRE-12. HETEROGENOUS RESPONSE OF IDH-MUTANT AND IDH-WT GLIOMA TO NAMPT INHIBITION
por: Rahman, Masum, et al.
Publicado: (2021)

Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm
por: Issa, Ghayas C., et al.
Publicado: (2021)

Characterization of TET and IDH gene expression in chronic lymphocytic leukemia: comparison with normal B cells and prognostic significance
por: Van Damme, Michaël, et al.
Publicado: (2016)

Mutational Hotspot of TET2, IDH1, IDH2, SRSF2, SF3B1, KRAS, and NRAS from Human Systemic Mastocytosis Are Not Conserved in Canine Mast Cell Tumors
por: Zorzan, Eleonora, et al.
Publicado: (2015)

Updates in IDH-Wildtype Glioblastoma
por: Melhem, Jawad M., et al.
Publicado: (2022)

Therapies for IDH-Mutant Gliomas
por: Alshiekh Nasany, Ruham, et al.
Publicado: (2023)

“ASXL1”-erating inflammation and bone marrow fibrosis in myeloproliferative neoplasms
por: Gleitz, Hélène F.E., et al.
Publicado: (2022)

IDH1/IDH2 but Not TP53 Mutations Predict Prognosis in Bulgarian Glioblastoma Patients
por: Stancheva, Gergana, et al.
Publicado: (2014)

Consequences of IDH1/2 Mutations in Gliomas and an Assessment of Inhibitors Targeting Mutated IDH Proteins
por: Kaminska, Bozena, et al.
Publicado: (2019)

Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers
por: Unruh, Dusten, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_p7ie3bvf9kem8sj7mm2p45mlba